title: [Drug-induced hypersensitivity syndrome in internal medicine: diagnostic and therapeutic traps. Eight observations].
abstract: OBJECTIVE
  Drug-induced hypersensitivity syndrome (DIHS) is an acute and severe drug reaction. Manifestations include severe skin lesions, fever, nodal enlargement, blood eosinophilia and multisystemic involvement. The severe systemic manifestations of DIHS are responsible for a 10% mortality rate. The pertinence of corticosteroid therapy is discussed.
  
  
  METHODS
  The authors report eight retrospective cases of DIHS obtained from the PMSI (Programme de Médicalisatiopn des Systèmes d'Information) between November 1991 and November 1998.
  
  
  RESULTS
  The series consisted of five male and three female patients (mean age: 52.6 years; range: 23-83 years). The interval between the introduction of the drug and the onset of the reaction varied from two to eight weeks. Due to severe systemic manifestations, three patients were given corticosteroid therapy. Healing of skin and systemic disorders resolved with a mean delay of 4.4 weeks (range: 1 to 56 weeks).
  
  
  CONCLUSIONS
  DIHS can be a diagnostic trap, as there are no diagnostic criteria for DIHS. Only the association of multiple arguments such as the time to the occurrence of symptoms, clinical similarity to many infectious illnesses, hypereosinophilia, atypical lymphocytosis, etc. may help guide diagnosis. DIHS can also be a therapeutic trap, as prompt withdrawal of the offending drug is essential to minimize morbidity. Although still controversial in the literature, the pertinence of corticosteroid therapy may be discussed in case of severe systemic effects. Patch testing can be a valuable tool to determine the responsibility of a drug; however it proves to be useful only when positive.
authors.affiliation: Service de médecine interne A, hôpital Dupuytren, CHU, 2, avenue Martin-Luther-King, 87042 Limoges, France.
authors.forename: A
authors.initials: A
authors.lastname: Sparsa
authors.forename: V
authors.initials: V
authors.lastname: Loustaud-Ratti
authors.forename: M
authors.initials: M
authors.lastname: Mousset-Hovaere
authors.forename: P
authors.initials: P
authors.lastname: De Vencay
authors.forename: V
authors.initials: V
authors.lastname: Le Brun
authors.forename: E
authors.initials: E
authors.lastname: Liozon
authors.forename: P
authors.initials: P
authors.lastname: Soria
authors.forename: C
authors.initials: C
authors.lastname: Bédane
authors.forename: M L
authors.initials: ML
authors.lastname: Bouyssou-Gauthier
authors.forename: S
authors.initials: S
authors.lastname: Boulinguez
authors.forename: J M
authors.initials: JM
authors.lastname: Bonnetblanc
authors.forename: E
authors.initials: E
authors.lastname: Vidal
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003875:Drug Eruptions / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007388:Internal Medicine; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013577:Syndrome
chemical_list: D000305:Adrenal Cortex Hormones